Trials / Completed
CompletedNCT00489528
Growth Hormone in the Treatment of HIV-Associated Wasting
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Recombinant Human Growth Hormone (Serostim) in the Treatment of HIV-Associated Catabolism/Wasting
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- EMD Serono · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to compare physical function and lean body mass in patients getting different doses of somatropin compared to patients not getting the drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Somatropin; Recombinant human growth hormone (r hGH) |
Timeline
- Start date
- 1997-07-01
- Completion
- 2002-03-01
- First posted
- 2007-06-21
- Last updated
- 2013-10-22
Source: ClinicalTrials.gov record NCT00489528. Inclusion in this directory is not an endorsement.